Coronary heart disease (CHD) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. According to Cardio Diagnostics Holdings (NASDAQ: CDIO), approximately 50% of individuals with coronary heart disease do not present with traditional risk factors, and conventional risk calculators have an average sensitivity of just 39%. In practical terms, that means many who appear healthy go on to have CHD and preventable cardiac events such as a heart attack.
For decades, cardiovascular risk assessment has centered on a checklist of factors—cholesterol levels, blood pressure, smoking history, diabetes status, family history, and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full biological picture of how heart disease develops. What makes CHD numbers particularly troubling is that so much of this is preventable.
Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics—fields that examine how genes are expressed and regulated at the molecular level. By analyzing DNA methylation patterns and genetic variants, these tests can identify molecular signatures of CHD that are invisible to traditional risk assessments. The company's approach aims to close the diagnostic blind spot that leaves many patients unaware of their underlying disease until it is too late.
The implications of this announcement are significant. If widely adopted, molecular precision testing could shift the paradigm from population-based risk scoring to individualized biological assessment. For patients, it means the possibility of early intervention before a heart attack occurs. For healthcare providers, it offers a tool that may improve detection rates beyond the 39% sensitivity of conventional calculators.
Cardio Diagnostics' technology represents a step toward more accurate identification of at-risk individuals, potentially reducing the number of preventable cardiac events. While traditional risk factors remain important, the company's epigenetic and genetic tests may provide a complementary layer of insight that could save lives.
For more information on Cardio Diagnostics Holdings, visit their newsroom at https://ibn.fm/CDIO. Forward-looking statements in this article involve risks and uncertainties as described in the company's SEC filings. The full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
